Bellicum Pharmaceuticals Stock News

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has r

In todays recent session, 0.77 million Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) shares changed hands as the companys beta touched 1.52. With the companys per share price at $1.53 changed hands at -$0.16 or -9.47% during last session, the market valuation stood at $14.91M. BLCMs last price was a discount, traded about -432.68% off its 52-week high Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM): This Is The Year For Success Over The Next Few Months Read More »

(RTTNews) - Bellicum Pharmaceuticals, Inc. (BLCM) reported positive interim data from ongoing phase 1/2 GoCAR-T clinical trials, including a confirmed partial response in the first cohort of mCRPC patients treated in the clinical trial for BPX-601. Charity Scripture, Chief Development Officer of Bellicum, said: "The early clinical activity we

Squarepoint Ops LLC cut its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 41.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,327 shares of the biopharmaceutical companys stock after selling 11,588 shares during the quarter. Squarepoint Ops LLC []

Vanguard Group Inc. raised its holdings in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 111.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 424,311 shares of the biopharmaceutical companys stock after acquiring an additional 223,524 shares during the quarter. Vanguard Group Inc. owned approximately 5.05% of []

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) saw a significant decrease in short interest during the month of October. As of October 29th, there was short interest totalling 626,200 shares, a decrease of 19.5% from the October 14th total of 777,700 shares. Currently, 7.5% of the company’s shares are sold short. Based on an average daily trading volume, […]

- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology -

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fai

The stock price of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) increased over 12% pre-market. This is why it happened.

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas M

HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity indu

HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered

HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial resul

Over the past couple of years, Bellicum Pharmaceuticals has made several changes that have streamlined their pipeline and their OpEx. Consequently, I have had to adjust my thesis and expectations. Bel

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2020 Results - Earnings Call Transcript